Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

J&J's Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso in NSCLC.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

Rybrevant can cause certain side effects ... Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication. Sharing your experience ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw ... by the US Food and Drug Administration (FDA) in 2021 and has since received full approval based on the PFS data.